Repligen/$RGEN
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Repligen
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Ticker
$RGEN
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
1,778
ISIN
US7599161095
Website
Repligen Metrics
BasicAdvanced
$7.2B
-
-$0.42
1.27
-
Price and volume
Market cap
$7.2B
Beta
1.27
52-week high
$182.52
52-week low
$102.97
Average daily volume
727K
Financial strength
Current ratio
6.793
Quick ratio
5.557
Long term debt to equity
33.672
Total debt to equity
34.435
Interest coverage (TTM)
1.84%
Profitability
EBITDA (TTM)
113.392
Gross margin (TTM)
51.45%
Net profit margin (TTM)
-3.53%
Operating margin (TTM)
6.48%
Effective tax rate (TTM)
-0.85%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
0.92%
Return on equity (TTM)
-1.16%
Valuation
Price to revenue (TTM)
10.979
Price to book
3.61
Price to tangible book (TTM)
14.5
Price to free cash flow (TTM)
61.175
Free cash flow yield (TTM)
1.63%
Free cash flow per share (TTM)
208.37%
Growth
Revenue change (TTM)
4.88%
Earnings per share change (TTM)
-200.24%
3-year revenue growth (CAGR)
-3.95%
10-year revenue growth (CAGR)
25.33%
3-year earnings per share growth (CAGR)
-45.08%
10-year earnings per share growth (CAGR)
7.22%
What the Analysts think about Repligen
Analyst ratings (Buy, Hold, Sell) for Repligen stock.
Bulls say / Bears say
Repligen reported a 10% revenue growth and a 72% increase in adjusted operating income in Q1 2025, indicating strong financial performance. (nasdaq.com)
The acquisition of 908 Devices' bioprocessing analytics portfolio enhances Repligen's process analytical technology, adding significant value to its offerings. (seekingalpha.com)
Analysts have set a 12-month average price target of $179.88 for Repligen, reflecting positive market sentiment. (benzinga.com)
Repligen's Q2 2023 revenues declined by 23.3% year over year, primarily due to a significant drop in COVID-related revenues. (nasdaq.com)
The company lowered its 2023 revenue guidance to $635-$665 million from the earlier projection of $720-$760 million, indicating potential challenges ahead. (nasdaq.com)
Repligen's net margin stands at -20.21%, suggesting challenges in achieving profitability. (benzinga.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Repligen Financial Performance
Revenues and expenses
Repligen Earnings Performance
Company profitability
Repligen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Repligen stock?
Repligen (RGEN) has a market cap of $7.2B as of July 05, 2025.
What is the P/E ratio for Repligen stock?
The price to earnings (P/E) ratio for Repligen (RGEN) stock is 0 as of July 05, 2025.
Does Repligen stock pay dividends?
No, Repligen (RGEN) stock does not pay dividends to its shareholders as of July 05, 2025.
When is the next Repligen dividend payment date?
Repligen (RGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Repligen?
Repligen (RGEN) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.